Eikon Therapeutics (NASDAQ:EIKN) outlined its development strategy for selective PARP1 inhibitors and its Werner helicase inhibitor during a discussion hosted by Cantor biotech analyst Imogen Mansfield. President, Chief Executive Officer and Board Chair Roger Perlmutter and MD Anderson Cancer Center
As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a turbulent four-year period of consolidation and the "Great Rationalization," a surge of institutional capital and the industrialization of Artificial Intelligence (AI) have ignited
